Cerebral Palsy Treatment Market Size (2024 - 2029)

Cerebral Palsy Treatment Market Analysis

The cerebral palsy treatment market is expected to register a significant CAGR of 4.4% during the study period.

• COVID-19 had a considerable effect on the cerebral palsy treatment market. The study published in the Journal of Rehabilitation Medicine in November 2020 stated that respiratory dysfunction was one of the leading causes of morbidity and mortality in individuals with cerebral palsy (CP). Individuals with pre-existing respiratory disorders were at greater risk for respiratory complications if they contracted COVID-19 due to the spasticity in the diaphragm, thereby increasing the risk of morbidity associated with cerebral palsy. 
• Furthermore, according to the study published in the Indian Journal of Orthopediatrics in January 2022, the results showed that the caregivers among cerebral palsy children had been largely affected by the COVID-19 pandemic in terms of functional decline, deformity progression, inability to receive regular physical treatment or orthotics, and behavioral problems.
• The factors propelling the cerebral palsy treatment market growth are the growing burden of cerebral palsy, the rise in investments, technological advancements, government initiatives, and other key strategies adopted by the key market players. According to the article published by Congress.gov in March 2022, cerebral palsy is the most common motor disability in children, affecting more than 1,000,000 Americans, 1 in 345 children, and over 17,000,000 people worldwide.
• The growing research and development activities in the development of therapeutics for cerebral palsy are driving the market growth. For instance, as per clinicaltrials.gov, in January 2022, Neurocrine Biosciences initiated a phase 3 clinical trial, a randomized, double-blind, placebo-controlled study to evaluate the efficacy of valbenazine versus placebo in participants aged 6 to 70 years for the treatment of dyskinesia due to cerebral palsy (DCP). The study is expected to be completed by August 2024. Positive responses from such studies evaluating the efficacies of existing treatments for cerebral epilepsy will increase its adoption, thus boosting the studied market during the study period.
• Moreover, rising strategic initiatives such as mergers and partnerships by key market players will expand the offerings in the market, which will boost the studied market. For instance, in April 2022, the Japanese subsidiary of Control Bionics signed an exclusive distribution agreement with Double Research and Development Co., Ltd. To start full-scale operations to better solve the communication challenges of people with severe disabilities in Japan through technology. Control Bionics has been working with users living with severe disabilities, including cerebral palsy (CP) and others.
• Rising investments in the market will propel technological innovation and expand the geographical presence, which will drive the market. For instance, in April 2022, Jupiter Lifeline Hospitals is planning to set up a state-of-the-art neuro-rehabilitation center in the United Kingdom with an investment of around 50 million pounds. The proposed rehabilitation center in the country is expected to have a 100-bed inpatient capacity, which will benefit patients with stroke, traumatic brain injury, cerebral palsy, spinal cord injury, Parkinson's disease, progressive and non-progressive neurological disorders, and sports injuries.
• Therefore, owing to the aforementioned factors, the studied market is expected to grow significantly during the study period. However, the side effects of drugs associated with cerebral palsy are expected to hinder market growth during the study period.

Cerebral Palsy Treatment Industry Segmentation

Cerebral palsy refers to a group of symptoms that involve difficulty moving and muscle stiffness (spasticity). It results from brain malformations that occur before birth as the brain is developing or from brain damage that occurs before, during, or shortly after birth. 

The cerebral palsy treatment market is segmented by disease type (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, mixed cerebral palsy), treatment type (surgery and medication), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. 

The report offers the value (in USD) for the above-mentioned segments.